Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
TERT and breast cancer are reported together in 2 articles.
Gene
TERT
- HGNC
- HGNC:11730
48articles
48mentions
2variants with confirmed gene link
Most co-reported phenotypes (articles)
thyroid cancer 25breast cancer 2colorectal cancer 2diabetes mellitus 2endometrial cancer 2leukemia 2prostate cancer 2hypertension 1
Reported variants (articles · ClinVar status)
Phenotype
Breast cancer
1,211articles
1,211mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
2 records shown · first 60MMTV Virus Detection, Survival Analysis, and Prognostic Relevance of Six Tumor Genes in Patients With Breast Cancer.
PMID 41983230 | PMCID PMC13071179 | DOI 10.1155/ijbc/3310843 · International journal of breast cancer · 2026 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TERT | “The genes associated with tumor suppression (p53, BRCA1, and BRCA2), telomere length maintenance (TERT), DNA damage response (FGFR2), and DNA repair (CHD1) are recognized for their intricate function in tumor genesis and progression.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “MMTV Virus Detection, Survival Analysis, and Prognostic Relevance of Six Tumor Genes in Patients With Breast Cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BRCA1 | “The genes associated with tumor suppression (p53, BRCA1, and BRCA2), telomere length maintenance (TERT), DNA damage response (FGFR2), and DNA repair (CHD1) are recognized for their intricate function in tumor genesis and progression.” | 0.98 | hgnc_dict_v1 |
| gene | BRCA2 | “The genes associated with tumor suppression (p53, BRCA1, and BRCA2), telomere length maintenance (TERT), DNA damage response (FGFR2), and DNA repair (CHD1) are recognized for their intricate function in tumor genesis and progression.” | 0.98 | hgnc_dict_v1 |
Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population.
PMID 31669704 | DOI 10.1016/j.ygeno.2019.09.017 · Genomics · 2020 · 7 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TERT | “Sanger Sequencing and immunohistochemistry was employed to investigate the TERT promoter mutations and TERT protein expression with their association to clinicopathological characteristics in over 2200 samples of Middle Eastern origin from 13 different types of cancers.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “The TERT promoter mutations were most frequently present in bladder cancer (68.6%), followed by central nervous system tumors (28.7%), thyroid cancer (15.4%), prostate cancer (9.3%), endometrial carcinoma (3.7%), rhabdomyosarcoma (1.4%), colorectal cancer (1%), epithelial ovarian carcinoma (0.7%) and breast cancer (0.7%).” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | colorectal cancer | “The TERT promoter mutations were most frequently present in bladder cancer (68.6%), followed by central nervous system tumors (28.7%), thyroid cancer (15.4%), prostate cancer (9.3%), endometrial carcinoma (3.7%), rhabdomyosarcoma (1.4%), colorectal cancer (1%), epithelial ovarian carcinoma (0.7%) and breast cancer (0.7%).” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | prostate cancer | “The TERT promoter mutations were most frequently present in bladder cancer (68.6%), followed by central nervous system tumors (28.7%), thyroid cancer (15.4%), prostate cancer (9.3%), endometrial carcinoma (3.7%), rhabdomyosarcoma (1.4%), colorectal cancer (1%), epithelial ovarian carcinoma (0.7%) and breast cancer (0.7%).” | 0.98 | phenotype_alias_lexicon_v2 |